Background and Objectives: Endometrial polyps are common in women presenting with subfertility, yet uncertainty persists regarding which lesions warrant removal and how best to integrate hysteroscopic management with contemporary fertility treatment pathways. This narrative review synthesizes current evidence on pathophysiological mechanisms, diagnostic approaches, fertility outcomes, and practical clinical management for women under 40 years of age. Materials and Methods: PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library were searched for English-language human studies published between January 2005 and December 2025. From 2352 records identified, 83 studies were included after screening of 1517 unique records (7 randomized controlled trials, 12 systematic reviews/meta-analyses, 14 prospective cohort studies, 31 retrospective cohort studies, 5 case–control and other study designs, 11 narrative reviews and supporting evidence studies, 1 clinical guideline, and 2 targeted 2025 additions). This structured narrative review employed a systematic search strategy to ensure comprehensive coverage, with evidence synthesized thematically in accordance with the SANRA guidelines. No formal risk-of-bias assessment or pre-registered protocol was used.Results: Across treatment modalities, hysteroscopic polypectomy was consistently associated with improved fertility outcomes. The landmark Pérez-Medina randomized trial reported a relative risk of 2.1 (95% CI 1.5–2.9) for pregnancy after polypectomy before intrauterine insemination. For IVF/ICSI, reported clinical pregnancy rates after polypectomy range from 53–72% and live birth rates from 43–66%. Proposed mechanisms include mechanical interference, chronic inflammation with cytokine dysregulation, altered endometrial receptivity (including dysregulation of HOXA10/HOXA11), and impaired decidualization. Conclusions: Current evidence supports hysteroscopic polypectomy as an effective intervention to improve fertility outcomes in subfertile women with endometrial polyps, particularly prior to intrauterine insemination. For IVF/ICSI, polypectomy of documented polyps appears beneficial, though evidence quality is moderate and heterogeneity exists across studies. It is critical to distinguish routine screening hysteroscopy before IVF from targeted polypectomy when a polyp has been documented. Contemporary guidance (including the 2024 SOGC guideline) favors polypectomy for symptomatic polyps and those that meet specific clinical criteria; for small asymptomatic polyps (<10 mm), individualized decision-making is appropriate, given limited direct evidence and the potential for spontaneous regression. Future research should clarify molecular predictors of polyp-associated infertility, optimal timing relative to fertility treatment, and long-term reproductive outcomes.
Göç et al. (Fri,) studied this question.